Patent intelligence · US
US 9475880
Anti-CD134 (OX40) antibodies and uses thereof
Anti-CD134 (OX40) antibodies and uses thereof
Patent details — US 9475880
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 25, 2016
- Expiration
- Oct 20, 2036
- Applicant
- Biocerox Products B.V.
- Claims
- 14
- CPC classes
- A61P, A61P35/00, A61P35/02, A61P35/04
Quick answer
US 9475880 (Anti-CD134 (OX40) antibodies and uses thereof) is held by Biocerox Products B.V.. Status: granted. Granted Oct 25, 2016. Expires Oct 20, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Biocerox Products B.V.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61P, A61P35/00, A61P35/02, A61P35/04, A61P37/04
More from Biocerox Products B.V.
Related pharmaceutical patents in our USPTO index.
-
US 12303551
Cellular immunotherapy compositions and uses thereof
granted -
US 12291557
Chimeric TIM4 receptors and uses thereof
granted -
US 11708423
Chimeric engulfment receptor molecules and methods of use
granted -
US 11697689
Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs
granted -
US 11655282
Chimeric engulfment receptor molecules
granted -
US 10675246
Orally administrable compositions comprising calcium
granted -
US 10307410
Mcl-1 modulating compounds for cancer treatment
granted -
US 10273307
Humanized anti-CD134 (OX40) antibodies and uses thereof
granted
Frequently asked questions
What is US patent 9475880?
US 9475880 (Anti-CD134 (OX40) antibodies and uses thereof) is held by Biocerox Products B.V.. Status: granted. Granted Oct 25, 2016. Expires Oct 20, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9475880?
Biocerox Products B.V. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 9475880 expire?
Our index shows an expiration date of Oct 20, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.